Zhejiang Taimei Medical Technology Co., Ltd. (Taimei Medical) has amended the terms of its previously announced investment vehicle, increasing the fund size by 45.00% to RMB329.50 million after admitting Jiaxing Yangtze River Delta Angel Venture Capital Partnership (Limited Partnership) as a new limited partner.

The Jiaxing YRD Angel Fund will inject RMB100.00 million into the partnership. Concurrently, Kaifeng Taimei—the general partner 50%-owned by Taimei Medical through subsidiary Zhiyan Haichung—will raise its own commitment from RMB2.27 million to RMB4.50 million. This adjustment adds an indirect RMB1.12 million exposure for Taimei Medical’s consolidated group.

Capital commitments from the existing limited partners remain unchanged: • Taimei Medical: RMB70.00 million • Taimei Intelligence: RMB30.00 million • Other original limited partners: unchanged amounts

With the larger capital base, the partnership expects to broaden both the number of investable projects and the average ticket size, although no specific targets have been identified to date.

According to Taimei Medical’s board, bringing in a government-led industrial fund strengthens the partnership’s financial resources and underscores official support for the company’s strategic direction. All other clauses of the original partnership agreement remain intact.

The directors, including independent non-executive members, state that the revised terms are conducted in the ordinary course of business, on normal commercial terms, and are fair and reasonable to shareholders.

The revised agreement was signed on 30 March 2026. Taimei Medical’s board currently comprises six executive and three independent non-executive directors.